Program
SYHX2008
A development code. Also written as “SYHX2008 injection”.
Its studies are mostly in Acromegaly, led by CSPC Pharmaceutical Group.
Furthest: phase 3, since May 29, 20264 company-led studies, 2 open or runningNext primary completion: Aug 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 42 open or running | phase 3since May 29, 2026 | Feb 13, 2023 | Aug 1, 2027phase 2 · NCT06505395 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 13, 2023First study: phase 1 study in AcromegalyFirst studyNCT05761431 · 56 enrolled · China
- Jul 10, 2024Phase 2 study in Gastrointestinal Neuroendocrine Pancreatic TumorNCT06505395 · 90 planned · China
- May 29, 2026Phase 3 study in Diagnosed With Acromegaly, Currently in the Active Stage of the DiseasePhase 3 reachedNCT07623824 · 154 planned
- Sep 7, 2026Phase 2 study in AcromegalyNCT07814651 · 78 enrolled · China
Ahead
- Aug 1, 2027Primary completion: phase 2 study in Gastrointestinal Neuroendocrine Pancreatic TumorNCT06505395
- Jul 31, 2029Primary completion: phase 3 study in Diagnosed With Acromegaly, Currently in the Active Stage of the DiseaseNCT07623824
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07814651Acromegaly · China | 2 | Completed | Apr 9, 2026 | 78 |
| NCT07623824Diagnosed With Acromegaly, Currently in the Active Stage of the Disease | 3 | Not yet recruiting | Jul 31, 2029 | 154 |
| NCT06505395Gastrointestinal Neuroendocrine Pancreatic Tumor · China | 2 | Recruiting | Aug 1, 2027 | 90 |
| NCT05761431Acromegaly · China | 1 | Completed | Jun 28, 2023 | 56 |
How it is read
Names in the registry
- “SYHX2008”, 2 entries
- “SYHX2008 injection”, 2 entries
Codes read as this program: SYHX2008.
Conditions, from the studies’ own filings
- Acromegaly, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.